Patent ID: 9499819
Filing Date: 2016-11-22
CPC Classification: A61K,A61P,C12N

Claim Text:
1. A method of treating inflammatory bowel disease comprising orally administering to a patient in need thereof an oral dosage form comprising an amount of anti-SMAD7 antisense oligonucleotide or a pharmaceutically acceptable salt thereof, wherein about 10% to about 30% of the amount of the anti-SMAD7 antisense oligonucleotide is released in an environment of pH of 6.6 from the oral dosage form over a period of 30 minutes in an HPLC dissolution method and substantially none of the amount of anti-SMAD7 antisense oligonucleotide is released from the oral dosage form in an environment of pH of 1.0 over a period of 120 minutes in an HPLC dissolution method.